Results 11 to 20 of about 28,689 (318)

A potential role of ruxolitinib in leukemia [PDF]

Expert Opinion on Investigational Drugs, 2011
An increased understanding of cellular signaling pathways, like the JAK?STAT pathway, and the identification of the JAK2 V617F mutation in the classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), has generated great interest in the development of targeted JAK2 inhibitors. In a recently completed Phase I?II study, ruxolitinib, a
Kiran Naqvi, Srđan Verstovšek, Hagop M. Kantarjian, Farhad Ravandi   +3 more
openalex   +4 more sources

Traffic lights for ruxolitinib [PDF]

Blood, 2017
In this issue of Blood , Newberry et al provide evidence that clonal evolution in patients with myelofibrosis (MF) who are receiving therapy with ruxolitinib correlates with discontinuation of treatment, mainly because of loss of response or progression, and also predicts shorter survival thereafter ...
Alessandro M. Vannucchi, Paola Guglielmelli   +1 more
openalex   +4 more sources

Ruxolitinib for Myelofibrosis [PDF]

New England Journal of Medicine, 2012
Myelofibrosis (MF), a myeloproliferative neoplasm, is a disease associated with a significant burden of symptoms, shortened survival and an array of standard treatment regimens which have historically lacked impact and efficacy. The discovery in 2005 of the highly prevalent JAK2V617F-activating tyrosine kinase mutation, strongly associated with ...
Steffen, Koschmieder, Adriane, Koppelle, Hans, Seifert   +2 more
openaire   +6 more sources

c-Src binds to the cancer drug Ruxolitinib with an active conformation. [PDF]

PLoS ONE, 2014
The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms. In addition, Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase.
Yankun Duan, Lin Chen, Yongheng Chen, Xue-gong Fan   +3 more
doaj   +1 more source

Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation

Frontiers in Pharmacology, 2021
Bronchiolitis obliterans syndrome (BOS) is a life-threatening pulmonary manifestation of chronic graft versus host disease (cGVHD) post-allogeneic hematopoietic stem cell transplantation (HSCT), without clear standard of care.
Yanmin Zhao, Yanmin Zhao, Guifang OuYang, Jimin Shi, Jimin Shi, Yi Luo, Yi Luo, Yamin Tan, Yamin Tan, Jian Yu, Jian Yu, Huarui Fu, Huarui Fu, Xiaoyu Lai, Xiaoyu Lai, Lizhen Liu, Lizhen Liu, He Huang, He Huang   +18 more
doaj   +1 more source

Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms

Blood Cancer Journal, 2023
The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are chronic malignancies associated with high-risk complications and suboptimal responses to JAK inhibitors such as ruxolitinib.
Charly Courdy, Loïc Platteeuw, Charlotte Ducau, Isabelle De Araujo, Emeline Boet, Ambrine Sahal, Estelle Saland, Valérie Edmond, Suzanne Tavitian, Sarah Bertoli, Pierre Cougoul, Fanny Granat, Laura Poillet, Caroline Marty, Isabelle Plo, Jean-Emmanuel Sarry, Stéphane Manenti, Véronique Mansat-De Mas, Carine Joffre   +18 more
doaj   +1 more source

Exploring redox vulnerabilities in JAK2V617F-positive cellular models

Hematology, Transfusion and Cell Therapy, 2021
Background: In Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) models, reactive oxygen species (ROS) are elevated and have been implicated in genomic instability, JAK2/STAT signaling amplification, and disease progression. Although the
Keli Lima, Lucia Rossetti Lopes, João Agostinho Machado-Neto   +2 more
doaj   +1 more source

Enzalutamide and Ruxolitinib [PDF]

Hospital Pharmacy, 2013
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Dominic A. Solimando, Susan A. Hobson, J. Aubrey Waddell   +2 more
openaire   +3 more sources

Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review

Frontiers in Oncology, 2021
Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis and lacks uniform treatment guidelines. Several studies confirmed the efficacy of ruxolitinib in hematological malignancies with PCM1-JAK2 fusion, but ...
Yingxin Sun, Yingxin Sun, Yifeng Cai, Jia Chen, Jia Chen, Jiannong Cen, Jiannong Cen, Mingqing Zhu, Mingqing Zhu, Jinlan Pan, Jinlan Pan, Depei Wu, Depei Wu, Aining Sun, Aining Sun, Suning Chen, Suning Chen   +16 more
doaj   +1 more source

JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid‐derived suppressor cells via the JAK/STAT and ROS‐MAPK/NF‐κB signalling pathways in acute graft‐versus‐host disease

Clinical & Translational Immunology, 2023
Objectives Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, demonstrates efficacy for treating steroid‐resistant acute graft‐versus‐host disease (SR‐aGVHD) following allogeneic stem cell transplantation (allo‐HSCT).
Yigeng Cao, Jiali Wang, Shan Jiang, Mengnan Lyu, Fei Zhao, Jia Liu, Mingyang Wang, Xiaolei Pei, Weihua Zhai, Xiaoming Feng, Sizhou Feng, Mingzhe Han, Yuanfu Xu, Erlie Jiang   +13 more
doaj   +1 more source